This document outlines a SWOT analysis for Abbott Laboratories, a pharmaceutical company founded in 1888. Some strengths include its global presence, history of innovation, and diverse product line including nutritional products. Weaknesses include upcoming patent expirations, high research costs, recent layoffs, and declining market share due to pricing pressures and competition. Opportunities include product innovation, expanding into rural markets, and shifting to treat chronic conditions. Threats include government policies, aggressive generic competition, litigation cases, and impact of recalls on investor confidence.

1. SWOT Analysis
By- Pritam singh
MBA PM-06

2. Founded in 1888 from the kitchen of Chicago
Doctor, Wallace C. Abbott
One of oldest most successful pharmaceutical
companies in the world
The company manufactures a number of
nutritional and pharmaceutical products,
laboratory diagnostics, pharmaceutical
therapies and medical devices

4. Global Presence
Innovation Leader in Industry
 Duphalac enema
 Tutaferon
Over 100 Years Success And Experience
Environmental Management & Image
 Reduce CO2 emission by 15%
 Reduce water intake by 50%

5. Diverse Product Line
 Specialized medicine and nutri supplements for
infants, children and adults
Nutritional Products
 E.g.- similac, pediasure, ensure and nutripals
 Contributes approx. 16% of its annual sales

6. Upcoming Expiring Patent
 bioxin- 33%loss in sale
 depakote
High Research Costs
 Inaugurated 2 R&D facilities in China and
Singapore
 Invested $3.7billion
Recent Company Layoffs
 6% of its workforce laid off in last two years

7. Declining Market Share
 EU pricing pressure
 Intensifying generic competition
Limited Investor Confidence
 Fall in growth rate during 2011-12
 21% to 10.9%
Product Callbacks
 Similac powder in plastic container
 Refused by US FDA

8. Product Innovation
 Ensure- a meal replacement shake
 Treat obesity by suppressing appetite
shift from acute to chronic
 Heart disease, stroke, diabetes etc
Rural market
 3% increase in sale over a 3 year period 2010-
13
 Empowered patient

9. Government policies
 DPCO 2013 affected Thyronorm, Obimet,
Epilex
Aggressive Competition From Generics
 Depakote faced generic competition
 Prices up to 80%less than brand name
Litigation cases
 against Ranbaxy Laboratories
 22.5million’s Tricor lawsuit on royalty issue

10. Abbott India Financial
report 2013
 Company outperform
the Indian pharma
market with 14.1%
growth where the market
grew by 10.1%
Duphaston,Udiliv and
Duphalac–together
generate more than 250
Crores in revenue.
2500
2000
1500
1000
500
0
Total revenue in cr.
1510
1675
2345
revenue in cr

11. http://en.wikipedia.org/wiki/Abbott_Laboratories
http://www.lawyersandsettlements.com/articles/depakote/de
pakote-lawsuit-side-effects
http://www.biojobblog.com/
http://www.drugpatentwatch.com/
http://www.worldpharmanews.com/abbott/874-abbott-to-acquire-
nutrition-businesses-expanding-presence-in-india>
http://abbottnutrition.com/about-us/about-abbott-nutrition>
http://www.drugs.com/manufacturer/abbott-laboratories-
2.html>